Aptevo Therapeutics and Alligator Bioscience announce positive interim data from Phase 1 trial for ALG.APV-527 in treating solid tumors likely to express tumor antigen 5T4.
AI Assistant
APTEVO THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.